RECRUITINGPhase 1INTERVENTIONAL

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients

About This Trial

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with the following suspected or diagnosed cancer types: - Adrenal cancer - Anal cancer - Bladder cancer - Brain cancer - Breast cancer - Cancer of unknown primary (CUP) - Cervical cancer - Cholangiocarcinoma - Colorectal cancer - Esophageal cancer - Gastric cancer - Head and neck cancer - Hematologic cancer - Hepatocellular carcinoma - Lung cancer - Medullary thyroid cancer - Neuroendocrine neoplasias - Ovarian cancer - Pancreatic cancer - Penile cancer - Peritoneal cancer - Pleural cancer - Prostate cancer - Sarcoma - Salivary gland cancer - Solitary fibrous tumor - Skin cancer - Testicular cancer - Thymus cancer - Thyroid cancer - Urothelial cancer - Uterus cancer - Vaginal cancer - Patients are ≥ 18 years old at the time of the radiotracer administration - Patient can provide written willing to sign a consent form - Patient is able to remain still for duration of imaging procedure (up to one hour) Who Should NOT Join This Trial: - Patient is pregnant or nursing - Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients with the following suspected or diagnosed cancer types: * Adrenal cancer * Anal cancer * Bladder cancer * Brain cancer * Breast cancer * Cancer of unknown primary (CUP) * Cervical cancer * Cholangiocarcinoma * Colorectal cancer * Esophageal cancer * Gastric cancer * Head and neck cancer * Hematologic cancer * Hepatocellular carcinoma * Lung cancer * Medullary thyroid cancer * Neuroendocrine neoplasias * Ovarian cancer * Pancreatic cancer * Penile cancer * Peritoneal cancer * Pleural cancer * Prostate cancer * Sarcoma * Salivary gland cancer * Solitary fibrous tumor * Skin cancer * Testicular cancer * Thymus cancer * Thyroid cancer * Urothelial cancer * Uterus cancer * Vaginal cancer * Patients are ≥ 18 years old at the time of the radiotracer administration * Patient can provide written informed consent * Patient is able to remain still for duration of imaging procedure (up to one hour) Exclusion Criteria: * Patient is pregnant or nursing * Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data

Treatments Being Tested

PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Fludeoxyglucose F-18

Given IV

RADIATION

Gallium Ga 68 FAPi-46

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Locations (1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, United States